Comparative efficacy of biologic agents for severe chronic rhinosinusitis with nasal polyps: Systematic review and network meta-analysis.

J Allergy Clin ImmunolJul 3, 2026 (epub)
Clinical ResearchOtolaryngology (ENT)

Konstantinos Ouranos, Mark Michael, Evangelia K Mylona et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis evaluated the efficacy and safety of seven biologic agents for severe chronic rhinosinusitis with nasal polyps (CRSwNP) in 3,642 patients. At 20-24 weeks, dupilumab and stapokibart showed greater reductions in nasal polyp score (NPS) and nasal congestion score (NCS) compared to other agents. No significant differences were found between dupilumab and stapokibart.

Key findings

  • Dupilumab and stapokibart produced greater reductions in NPS and NCS at 20-24 weeks compared to depemokimab, omalizumab, and benralizumab.
  • At 48-56 weeks, dupilumab and tezepelumab showed greater reductions in NPS and NCS than depemokimab, mepolizumab, or benralizumab.
  • Safety profiles were comparable across all biologic agents evaluated.

Why it matters

Understanding the comparative efficacy of biologic agents for severe CRSwNP can guide clinicians in selecting appropriate treatments, potentially improving patient outcomes and quality of life.

Source

PubMed · PMID 42398863

Published in J Allergy Clin Immunol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.